Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Multiple Sclerosis (MS)

VLST Corp

Parents

*Portfolio Companies: Accelerator Corporation
A biologic therapy for the treatment of multiple inflammatory disorders which has annual sales already exceeding $1.9 billion in
Co-founded by Dr Craig Smith
Co-Founded by Dr Ray Goodwin
Co-Founded by Steven Wiley
co-inventors of Enbrel
combines cutting-edge bioinformatics and proteomics with an in-depth understanding of key inflammatory processes
has already identified a number of highly pre-validated cellular targets and counter structures and is evaluating their therapeu
novel and streamlined approach to speed the development of effective therapeutics for the treatment of inflammatory and autoimmu
Platform for improved identification and validation of cell targets for drug development
provide a rapid and rational approach to identifying new targets for the development of novel biologic therapies
Seattle, Washington
VENTURE FUNDING TOTAL $55M - Texas Pacific Group, MPM Capital, ARCH Venture Partners, OVP Venture Partners, Amgen Ventures, MedImmune Ventures, WRF Capital (2006)
VLST Corporation
VLST Cuts Scientific Group As Focus Shifts to Clinical Trials (2012)
VLST left the incubator in June 2006 after raising $55 million from investors.